Kidney cancer
Oncology· 7 reviewed drugs· 4043 cited findings behind them
What the regulatory reviews cover
Regulatory review documents for several drugs used in the treatment of kidney cancer are available in this library. These include Welireg, indicated for advanced renal cell carcinoma (RCC) following specific prior therapies, which showed a median PFS of 5.6 in its belzutifan arm. Cabometyx, for advanced RCC after prior therapy, reported a 10% discontinuation rate due to adverse events in its pivotal phase 3 RCC study. Votrient, for first-line treatment of advanced RCC, demonstrated an OS HR (Pazopanib 1L vs Placebo) of 0.74. Inlyta axitinib, for the treatment of renal cell carcinoma, showed a PFS Hazard Ratio (axitinib vs sorafenib) of 0.670.
It is important to note that these drugs were studied in different clinical trials, and therefore, the reported figures are not directly comparable head-to-head. Other drugs with review documents in this library include Lenvima, Afinitor, and Kisplyx, though their indications in the provided text do not directly specify kidney cancer.
The drugs — one cited result each
| Welireg Merck & Co., Inc. | median PFS: 5.6 Merck & Co., Inc. — Welireg FDA Review (NDA/BLA 215383, 2026, p.116 |
| Lenvima Eisai Co., Ltd. | 584 cited findings on the drug page → |
| Cabometyx Ipsen S.A. | Discontinuation due to adverse events in pivotal phase 3 RCC study: 10 Ipsen S.A. — Cabometyx EMA EPAR public assessment report (EM, p.45 |
| Votrient Novartis AG | OS HR (Pazopanib 1L vs Placebo): 0.74 Novartis AG — Votrient EMA EPAR public assessment report (EM, p.48 |
| Afinitor Novartis AG | 287 cited findings on the drug page → |
| Inlyta axitinib Pfizer Inc. | PFS Hazard Ratio (axitinib vs sorafenib): 0.670 EMA EPAR, p.52 |
| Kisplyx Eisai Co., Ltd. | 136 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.